The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...
For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
GlobalData on MSN
J&J’s Caplyta doubles remission rate in MDD patients
J&J presented the new analysis from three Phase III trials of Caplyta in MDD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results